ROCKVILLE - MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 7 June 2024 and 10 June 2024, Maher Masoud, President and Chief Executive Officer of the Company, using personal funds, purchased 100,000 shares on the open market of common stock in the Company ('Common Stock').

The 100,000 shares of Common Stock were purchased at an average price of $4.8907 per Common stock.

Contact:

David Deuchler

Tel: +1 415-937-5400

Email: ir@maxcyte.com

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx, STx, GTx and VLx ; a portfolio of proprietary related processing assemblies or disposables and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.

(C) 2024 Electronic News Publishing, source ENP Newswire